At a glance
ClinicalIndex Comparison Record- ✓Diagnosed with psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis
- ✓Starting infliximab treatment for the first time at this medical institution after drug launch
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis)
In Brief
An observational study evaluating Infliximab [infliximab biosimilar 3] for Psoriasis Vulgaris and 3 related conditions. Completed, enrolled 10 participants across 1 site.
Detailed Summary
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under actual status of use.
Study Details
Timeline
Interventions
\<Psoriasis\> The usual dose is 5 mg as Infliximab (Genetical Recombination) \[Infliximab Biosimilar 3\] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.